Officials warn of possible Remdesivir shortage in Europe
Officials across Europe warn that Remdesivir shortages could provide a significant challenge to physicians hoping to treat patients as an infection spike across the continent heralds a possibly devastating second wave.
A study published this week in The New England Journal of Medicine found that the therapeutic drug remedies severe that President Trump has been taking was proving particularly effective at both reducing the mortality rate amongst covert 19 patients but also accelerating their discharge from hospital on. Although demand for the drug in the United States has actually fallen in recent weeks here in Europe, there's beena significant shortfall in certain countries off remedies severe now. The most basic explanation is that the manufacturer behind this drug, Juliet, is not producing enough of the stuff on. Experts say that governments here in Europe have not ordered enough in advance. You have to imagine that one company supplying the whole world has to be able to foresee where to move things on, that this is not always possible if you don't know the patient leaders I mentioned before. So the level of collaboration when you're saying how does it happen? It happens when the level of collaboration isn't good enough and when the data is not available and when the forecasts are not reliable. So we have to improve on all of those areas and I think it's very clear to everybody. That's a work in progress now. The United States initially ordered 500,000 treatment courses of remedies over here in Europe, that number was just 30,000, although governments now insisting they do have enough supply as of this week because of an attempt by the European Union to buy up the drug to share more equitably amongst countries that needed it. There is a concern amongst experts. We've spoken to that as the winter approaches as we see infection cases rise as we see hospitalization rates increase. Without better data sharing and coordination between health ministries, hospitals on drug manufacturers, there could be further shortfalls of necessary treatment in the months to come. Fillon marks NBC News London.